Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Plecanatide, a uroguanylin analog, activates the guanylate cyclase C receptors in the epithelial lining of the gastrointestinal tract in a pH-dependent fashion initiating (1) the conversion of intracellular guanosine triphosphate to cyclic guanosine monophosphate, which increases the activity of the cystic fibrosis transmembrane conductance regulat...
Alternative Titles
Full title
Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2260026058
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2260026058
Other Identifiers
ISSN
0114-5916
E-ISSN
1179-1942
DOI
10.1007/s40264-018-0781-9
